ADVERTISEMENT
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 234 entries already.
The BIOTECH SUMMIT AUSTRIA 2024 in Innsbruck brought together leaders, innovators and investors to network, interact and to enjoy being part of the booming Austrian biotech community. It showcased science, funding and collaboration opportunities, setting the stage for 2025 in Graz.
Novo Nordisk is putting down up to US$362m to tap into Ascendis’ TransCon technology for treatments in metabolic and cardiovascular diseases. The pharma powerhouse has its sights set on developing a once-monthly GLP-1 receptor agonist.
Purespring Therapeutics, a pioneering gene therapy company focused on transforming kidney disease treatment, has raised £80 (€96m) in an oversubscribed Series B round. Led by Sofinnova Partners, this funding also drew support from Gilde Healthcare, Forbion, British Patient Capital, and Syncona Limited.
Swedish clinical-stage pharmaceutical company Vicore Pharma has secured SEK100m, supported by existing and new investors. The injection of capital will allow the company to scale the clinical development of its portfolio of therapies in respiratory and fibrotic diseases.
Fab’entech, a French biopharma company, has secured a loan worth €20m from the European Investment Bank (EIB) under the HERA Invest programme, aimed at bolstering Europe’s preparedness against biological threats.
Antimicrobial resistance (AMR) poses a huge threat to the prevention and treatment of a growing number of infections caused by bacteria, parasites, viruses, and fungi. A public-private partnership involving nine European projects and 98 organisations is now calling for long-term investment to maintain Europe’s ability to research and develop new antibiotics.
Agri-biotech SOLASTA Bio Ltd. has raised US$14m in a Series A funding round led by Forbion. With the money, the UK company will advance its first-of-a kind peptide-based bioinsecticide.
A Phase III trial evaluating AstraZeneca and Daiichi Sankyo’s potential “blockbuster” lung cancer drug Dato-DXd showed no significant improvement over standard chemotherapy. Investors reacted quickly: AstraZeneca’s share price dropped 5% following the announcement.
PulseSight Therapeutics SAS was launched on Wednesday, backed by seed financing from Pureos Bioventures and ND Capital. The company introduces a disruptive delivery platform in ophthalmology biotech, focusing on the development of non-viral gene therapies coupled with minimally-invasive delivery technology.
Forbion has spearheaded a €75m Series A financing in Norwegian biotech Calluna Pharma. The clinical-stage company resulted from the merger of Oxitope Pharma and Arxx Therapeutics.